Howard Mayer, M.D., of Shire, Joins Genocea Biosciences’ Board of Directors
March 06 2017 - 8:00AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing T cell-directed vaccines and immunotherapies,
today announced that Howard Mayer, M.D., senior vice president and
head of global clinical development at Shire plc, has joined its
board of directors. Genocea also announced that Kevin Bitterman,
Ph.D., a partner at Polaris Partners, will retire as a member of
the company’s board of directors. Dr. Bitterman served on Genocea’s
board since the company’s founding in 2006.
“It is my great pleasure to welcome Howard to our board of
directors,” said Chip Clark, president and chief executive officer
of Genocea. “As we advance our lead therapeutic vaccine candidate,
GEN-003 for the treatment of genital herpes, into pivotal clinical
development and prepare to enter the clinic with GEN-009, our
neoantigen cancer vaccine, we believe Howard’s deep industry and
clinical development expertise will prove invaluable to us. At the
same time, we would like to express our deep gratitude to Kevin for
his years of service on our board. Polaris was one of our founding
investors and Kevin has played an important role in the evolution
of Genocea from concept to today.”
Dr. Mayer commented on his appointment: “I am delighted to be
joining the Genocea board and I am excited by the prospect of
Genocea advancing the first new treatment for genital herpes
patients in nearly 20 years. I also believe the company’s ATLAS
technology has great potential in immuno-oncology and I look
forward to working with the Genocea board and the senior management
team to help advance the company’s clinical programs.”
Dr. Mayer joined Shire in 2012 and is responsible for global
clinical development across hematology, immunology, oncology,
genetic diseases, GI/metabolic, neuroscience and ophthalmology
therapeutic areas. Previously he served as chief medical officer at
EMD Serono, a division of Merck KGaA, since 2009. Prior to that, he
held a variety of global roles at Pfizer Inc. including head of
clinical development and medical affairs for Virology/Infectious
Diseases. Prior to joining Pfizer, he served as director of
Infectious Diseases Clinical Research at Bristol-Myers Squibb for
five years. Dr. Mayer obtained his BA from the University of
Pennsylvania and his M.D. from Albert Einstein College of Medicine
in New York, which was followed by an internship and residency at
Mount Sinai Hospital and an Infectious Diseases fellowship at
Harvard Medical School. He currently serves on the scientific
advisory boards of Macrolide Pharmaceuticals and Arsanis
Biosciences and has served on the board of Autism Speaks in New
England since 2011 and on the board of the Melmark Charitable
Foundation since 2016. In 2011, he was honored by PharmaVoice as
one of the 100 Most Inspiring People in the Life Sciences
Industry.
About Genocea Biosciences, Inc.Genocea is
harnessing the power of T cell immunity to develop life-changing
vaccines and immunotherapies. T cells are increasingly recognized
as a critical element of protective immune responses to a wide
range of diseases, but traditional discovery methods have proven
unable to identify the targets of such protective immunity. Using
ATLAS™, its proprietary technology platform, Genocea identifies
these targets to potentially enable the rapid development of
medicines to address critical patient needs. Genocea's pipeline
includes GEN-003, a novel T cell-enabled immunotherapy for genital
herpes currently in Phase 2 clinical development, and earlier-stage
investments in immuno-oncology. For more information, please visit
the company's website at www.genocea.com.
Forward-Looking StatementsStatements herein
relating to future business performance, conditions or strategies
and other financial and business matters, including expectations
regarding clinical developments, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act.
Genocea cautions that these forward-looking statements are subject
to numerous assumptions, risks and uncertainties, which change over
time. Factors that may cause actual results to differ materially
from the results discussed in the forward-looking statements or
historical experience include risks and uncertainties, including
Genocea's ability to progress any product candidates in preclinical
or clinical trials; the ability of ATLAS to identify promising
oncology vaccine and immunotherapy product candidates; the scope,
rate and progress of its preclinical studies and clinical trials
and other research and development activities; anticipated clinical
trial results; current results may not be predictive of future
results; even if the data from preclinical studies or clinical
trials is positive, regulatory authorities may require additional
studies for approval and the product may not prove to be safe and
efficacious; Genocea's ability to enter into future collaborations
with industry partners and the government and the terms, timing and
success of any such collaboration; risks associated with the
manufacture and supply of clinical and commercial product; the cost
of filing, prosecuting, defending and enforcing any patent claims
and other intellectual property rights; Genocea's ability to obtain
rights to technology; competition for clinical resources and
patient enrollment from drug candidates in development by other
companies with greater resources and visibility; the rate of cash
utilized by Genocea in its business and the period for which
existing cash will be able to fund such operation; Genocea's
ability to obtain adequate financing in the future through product
licensing, co-promotional arrangements, public or private equity or
debt financing or otherwise; general business conditions;
competition; business abilities and judgment of personnel; the
availability of qualified personnel and other factors set forth
under "Risk Factors" in Genocea's Annual Report on Form 10-K for
the fiscal year ended December 31, 2016 and other filings with the
Securities and Exchange Commission (the "SEC"). Further information
on the factors and risks that could affect Genocea's business,
financial conditions and results of operations is contained in
Genocea's filings with the SEC, which are available at www.sec.gov.
These forward-looking statements speak only as of the date of this
press release and Genocea assumes no duty to update forward-looking
statements.
For media:
Jennifer LaVin
O: 617-715-6687
jennifer.lavin@genocea.com
For investors:
Jonathan Poole
O: 617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024